

## COVID-19 Testing and Specimen Collection at Pharmacies Billing Guidance

### Claims Submission Information

- Claims can be submitted electronically starting **August 15, 2020**
- COVID-19 diagnostic testing must be FDA approved or granted Emergency Use Authorization (EUA) CLIA-waived **and pharmacies** must be within the network of participating test administrators
  - FDA approved or granted Emergency Use Authorization (EUA) CLIA-Waived point-of-care diagnostic testing can be found at:
    - <https://www.fda.gov/medical-devices/emergency-situations-medical-devices/emergency-use-authorizations-medical-devices#COVID19IVD>

### *Billing Instruction for Lab Specimen Collection*

NCPDP D.0. Claim Segment Field	Value
409-D9 (Ingredient Cost Submitted)	>\$0.00
444-E9 (Pharmacist ID)	Enter Pharmacist National Provider Identifier Number (NPI ) Number
411-DB (Prescriber ID)	Please leave field blank*
440-E5 (Professional Service Code)	MA (Medication Administration)
438-E3 (Incentive Amount Submitted)	≥ \$0.01
426-DQ (Usual and Customary Charge)	≥ \$ in Incentive Amount Submitted (Row above)
436-E1 (Product/Service ID Qualifier)	03
407-D7 (Product/Service ID)	NDC/UPC (Examples include the below and are not limited to:) 60004-0417-80 99999-0992-11
442-E7 (Quantity Dispensed)	1
405-D5 (Day Supply)	1
473-7E (DUR/PPS Code Counter)	1

\* Effective August 15, 2020, claims should be submitted with blanks in the Prescriber ID field (411-DB)

*Billing Instruction for CILA waived COVID-19 testing*

NCPDP D.0. Claim Segment Field	Value
439-E4 (Reason for Service Code)	PP
440-E5 (Professional Service Code)	PT
441-E6 (Result of Service Code)	00
438-E3 (Incentive Amount Submitted Field)	≥ \$0.01
436-E1 (Product/Service ID Qualifier)	03
407-D7 (Product/Service ID)	NDC/UPC (Examples include the below and are not limited to:)  11877-0011-26 (ID Now COVID-19 In Vitro Kit)  14613-0339-08 (Sofia2 SARS Antigen FIA In Vitro Kit)
442-E7 (Quantity Dispensed)	1
405-D5 (Day Supply)	1
473-7E (DUR/PPS Code Counter)	1

- Pharmacies that are performing and billing for COVID-19 testing **should not bill for specimen collection**. Reimbursement for the test includes specimen collection and generating the lab report
- Pharmacies who are already being provided payment, from another source, for either lab specimen collection or for COVID-19 testing should not bill Affinity Health Plan in addition
- If you have not received information on how to enroll in the network of pharmacies wishing to provide COVID-19 testing service please contact Caremark at 866-488-4708